OAM
ISEE

Oppenheimer Asset Management’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Oppenheimer Asset Management’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-35
Closed – – 1718
2017
Q2 		$0 Sell
35
-47
-57% -$128 ﹤0.01% 1738
2017
Q1 		$0 Buy
+82
New +$347 ﹤0.01% 1699

Other funds holding ISEE

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Oppenheimer Asset Management's ISEE Position: Q3 2017 in Review

Oppenheimer Asset Management sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2017, closing a stake of 35 shares.

Oppenheimer Asset Management first reported a position in ISEE in Q1 2017 and held it in 2 quarters. The position peaked at $0 in Q2 2017. 67 funds tracked by Wall St. Rank hold ISEE as of Q3 2017.

  • Oppenheimer Asset Management reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Oppenheimer Asset Management sold 35 IVERIC bio, Inc. Common Stock shares in Q3 2017.
  • Oppenheimer Asset Management first reported a position in IVERIC bio, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Oppenheimer Asset Management's IVERIC bio, Inc. Common Stock position peaked at $0 in Q2 2017.
  • 67 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2017.

Based on Oppenheimer Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.